Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)

Mark A. Hull, Chief Investigator, University of Leeds

“Today’s presentation reflects years of commitment from the funder (Yorkshire Cancer Research), investigators, research teams, and, most importantly, the patients who took part in EMT2, helping to advance our understanding of whether IPE could improve outcomes in patients with metastatic colorectal cancer”

Mark A. Hull, Chief Investigator, University of Leeds

“An overall survival benefit without a corresponding progression-free survival benefit is not an unprecedented finding in oncology.”

Mark A. Hull, Chief Investigator, University of Leeds

“This type of oncology endpoint pattern can be observed where delayed effects on host anti-tumor immunity may influence long-term outcomes.”

Mark A. Hull, Chief Investigator, University of Leeds

“There are also several biologically plausible hypotheses, including direct anti-inflammatory or anti-neoplastic activity of prescription IPE and potential augmentation of host anti-tumor immune surveillance through effects on the gut microbiome.”

Mark A. Hull, Chief Investigator, University of Leeds

“These potential mechanisms remain investigational and require further analyses of the EMT2 dataset as well as further study.”

Steve Ketchum, President R&D and Chief Scientific Officer, Amarin

“We are encouraged by the presented findings, including the significant improvement in overall survival, a clinically important and meaningful endpoint in oncology and a key result that warrants further scientific evaluation.”

Steve Ketchum, President R&D and Chief Scientific Officer, Amarin

“These findings add to clinical and mechanistic evidence suggesting that highly purified prescription IPE may have biological effects of relevance to areas beyond cardiovascular disease.”

Aaron Berg, Chief Executive Officer, Amarin

“Perhaps the most exciting part of these findings is the new questions they allow us to ask regarding potential novel therapeutic pathways for VAZKEPA/VASCEPA”

Aaron Berg, Chief Executive Officer, Amarin

“These results give us an opportunity to explore whether this safe and proven therapy for cardiovascular risk reduction – which has been prescribed approximately 32 million times - could make a meaningful difference in the adjunctive care of colorectal cancer patients with liver metastases eligible to undergo liver surgery.”

Aaron Berg, Chief Executive Officer, Amarin

“Our team will continue to collaborate with the study sponsor to better understand the results and develop a clearer perspective on the potential opportunity.”

Aaron Berg, Chief Executive Officer, Amarin

“Patent protection in Europe through 2039 for VAZKEPA/VASCEPA provides a substantial runway to evaluate this type of opportunity and its potential to deliver long-term value for patients and shareholders.”